|
gptkbp:instanceOf
|
gptkb:antidepressant
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
gptkb:N06AA16
|
|
gptkbp:availableOn
|
gptkb:Australia
gptkb:India
gptkb:South_Africa
gptkb:United_Kingdom
|
|
gptkbp:CASNumber
|
gptkb:113-53-1
|
|
gptkbp:contraindication
|
severe liver disease
recent myocardial infarction
mania
|
|
gptkbp:discontinued
|
gptkb:United_States
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
8-17 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasInChIKey
|
gptkb:QFFGVLORLPOAEC-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C19H21NS
|
|
gptkbp:hasSMILES
|
CN(C)CCCN=C1C2=CC=CC=C2SC3=CC=CC=C13
|
|
gptkbp:hasUNII
|
0I6C2DBN35
|
|
gptkbp:IUPACName
|
3-(6H-dibenzo[b,e]thiepin-11-ylidene)-N,N-dimethylpropan-1-amine
|
|
gptkbp:KEGGID
|
gptkb:D07841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Dothep
gptkb:Prothiaden
gptkb:Thaden
|
|
gptkbp:mechanismOfAction
|
gptkb:norepinephrine_reuptake_inhibitor
gptkb:antihistamine
anticholinergic
alpha-1 adrenergic antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
295.44 g/mol
|
|
gptkbp:overdoseSymptoms
|
gptkb:death
gptkb:arrhythmia
coma
seizures
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:PubChem_CID
|
31513
29213
CHEMBL1407
DB00520
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
blurred vision
weight gain
drowsiness
dry mouth
urinary retention
|
|
gptkbp:synonym
|
dosulepin
|
|
gptkbp:usedFor
|
gptkb:depression
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Dosulepin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dothiepin
|